Compounds and methods for modulation of estrogen receptors
Number of patents in Portfolio can not be more than 2000
United States of America Patent
Stats
-
Feb 3, 2004
Grant Date -
May 8, 2003
app pub date -
Feb 27, 2002
filing date -
Mar 17, 1999
priority date (Note) -
Expired
status (Latency Note)
Importance
Abstract
Compounds that modulate the estrogen receptor (ER) are disclosed, as well as pharmaceutical compositions containing the same. In a specific embodiment, the compounds are selective modulators for ER-.beta. over ER-.alpha.. Methods are disclosed for modulating ER-.beta. in cell and/or tissues expressing the same, including cells and/or tissue that preferentially express ER-.beta.. More generally, methods for treating estrogen-related conditions are also disclosed, including conditions such as is breast cancer, testicular cancer, osteoporosis, endometriosis, cardiovascular disease, hypercholesterolemia, prostatic hypertrophy, prostatic carcinomas, obesity, hot flashes, skin effects, mood swings, memory loss, urinary incontinence, hairloss, cataracts, natural hormonal imbalances, and adverse reproductive effects associated with exposure to environmental chemicals.
First Claim
Family
International Classification(s)
- [Classification Symbol]
- [Patents Count]
Cited Art Landscape
Patent Citation Ranking
Recipient Email Address
Recipient Email Address
Comment
Recipient Email Address
Add to Portfolio(s)
To add this patent to one, or more, of your portfolios, simply click the add button.
This Patent is in these Portfolios:
Add to additional portfolios:
Last Refreshed On:
Changes done successfully